I so agree M. This abstract is a follow on to the presentation that generated so much hooplah at last years AAIC which fell like a rock after everyone at AAIC realized how unsupported the hype was. Finally this paper comes out in a peer reviewed journal with very thinly supported facts, etc. Of course there is no information here about a Phase 3 because there is no data to report from any Phase 3 trial. Continued attempts to displace facts with fiction are tiresome.
Biogen Paper, page-21
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ATH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
-0.001(25.0%) |
Mkt cap ! $15.96M | |||
| Open | High | Low | Value | Volume |
| 0.4¢ | 0.4¢ | 0.3¢ | $4.734K | 1.341M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 49 | 30295639 | 0.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.4¢ | 129917446 | 34 |
View Market Depth
| Last trade - 15.44pm 15/10/2024 (20 minute delay) ? |
| ATH (ASX) Chart |